glp-1 ckd Potential kidney-protective and other effects of receptor GLP-1 Use in Non-Diabetics Associated

New Research About the GLP-1 Weight Loss Plateau A new three-year study on Zepbound ( tirzepatide ) shows that most people hit a weight loss plateau within the first six to 12 months

2020;3(3):CD005004

The potential benefits of semaglutide 1 mg once weekly in people with atherosclerosis and peripheral artery disease (Figs 3, 4) are being examined over 52 weeks, with the primary outcomes of treadmill walking distance and secondary outcomes of changes in quality of life and pain free walking distance (NCT04560998)

Staying hydrated, trying to eat smaller meals more often and following the nausea tips listed above

doi:10.1056/NEJMoa2107519 17

and Germany